CompletedNot Applicable

Medication Adherence With Telehealthcare Medication Therapy Management

United States375 participantsStarted 2019-11-18

Plain-language summary

Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma (MATCH) is a multi-center, randomized parallel group study targeted to an at-risk population of Adolescents and Young Adults (AYA) with uncontrolled asthma who have poor adherence with prescribed Inhaled corticosteroid (ICS) therapy.

Who can participate

Age range

12 Years – 35 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 12 through 35 years * Speaks English or Spanish * Physician diagnosed asthma (without any other co-morbid pulmonary disease) * Prescribed ICS treatment for at least 3 months prior to screening * Adherence to Refills and Medication Scale (ARMS) 7-item questionnaire score of \>8 (low or moderate adherence) * Current use of albuterol metered dose inhaler (MDI) for rescue: ProAir, Ventolin, albuterol sulfate (from Prasco or Teva) * Uncontrolled asthma: * Symptomatic asthma defined as 3 of the following in the past 4 weeks: * Daytime symptoms of asthma more than twice per week * Any night awakening due to asthma * Rescue inhaler use for symptoms more than twice per week * Any activity limitation due to asthma; OR * Asthma Control Test score ≤19 * Has iPhone or Android smart phone with Short Message Service (SMS) * Has access to reliable WiFi service and a device with capability for telemedicine study visits * Ability to understand and willingness to sign consent documents * Evidence of Propeller sensor connection in the 4-week run-in period Exclusion Criteria: * Use of an investigational treatment in the previous 30 days. * Previous enrollment in MATCH Structured Interviews ( Aim 1) * Currently enrolled in an intervention trial * Currently uses an ICS not compatible with the Propeller sensor * Inability to comply with study procedures, including: * Inability or unwillingness to provide informed consent (or assent in the case of a minor). * Inability to…

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Proportion of ICS Inhaler Adherent Days

Timeframe: Up to 12 months

Percent Cumulative Incidence Severe Exacerbation

Timeframe: Up to 12 months

Trial details

NCT IDNCT03978936

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-03-14

Results submitted2026-03-10

View on ClinicalTrials.gov More Uncontrolled Asthma trials